1Leonetti G.Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension:a double blind,prospective,randomised clinical trial[J].Curr Med Res Opin,2005,21(6):951-958.
2Satoh Y,Ichihashi M,Okumura K,et al.Studies on nilvadipine.I.Synthesis and structure-activity relationships of 1,4-dihydropyridines containing novel substituents at the 2-position[J].Chemi&Pharm Bull,1991,39(12):3189-3201.
3Brogden RN,McTavish D.Nilvadipine:a review of its pharmacodynamic and pharmacokinetic properties,therapeutic use in hypertension and potential in cerebrovascular disease and angina[J].Drugs&Aging,1995,6(2):150-171.
4Motiwala F,Ojike N,Lippmann S.Dihydropyridine calcium channel blockers in dementia and hypertension[J].Curr Psych Rep,2013,12(8):41.
5Kennelly S,Abdullah L,Kennyl RA,et al.Apolipoprotein E genotype-specifi c short-term cognitive benefi ts of treatment with the antihypertensive nilvadipine in Alzheimer’s patientsan open-label trial[J].Int J Geriatr Psych,2012,27(4):415-422.
6Kennelly SP,Abdullah L,Paris D,et al.Demonstration of safety in Alzheimer‘s patients for intervention with an antihypertensive drug nilvadipine:results from a 6-week open label study[J].Int J Geriatr Psych,2011,26(10):1038-1045.
7Nakazawa M,Ohguro H,Takeuchi K,et al.Effect of nilvadipine on central visual fi eld in retinitis pigmentosa:a30-month clinical trial[J].Ophthalmologica,2011,225:120-126.
8Hanyu H,Hirao K,Shimizu S,et al.Nilvadipine prevents cognitive decline of patients with mild cognitive impairment[J].Int J Geriatr Psych,2007,12(22):1264-1266.
9Miyamae A,Koda S,Morimoto Y.Structural studies of a new dihydropyridine calcium channel antagonist,nilvadipine[J].Che&Pharm Bull,1986,34(8):3071-3078.
